CL-L1 and CL-K1 Complement Associated Pattern Recognition Molecules in Systemic Lupus Erythematosus

Anne Troldborg¹, Steffen Thiel², Lisbeth Jensen³, Magdalena Janina Laska², Søren Hansen⁴, Bent Deleuran^5,6, Jens Christian Jensenius² and Kristian Stengaard-Pedersen⁵, ¹clinical medicine, Aarhus University, Aarhus, Denmark, ²Biomedicine, Aarhus University, Aarhus, Denmark, ³Biomedicin, Aarhus University, Aarhus, Denmark, ⁴Department of cancer and inflammation research, University of Southern Denmark, Odense, Denmark, ⁵Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Biomedicin, Aarhus University, 8000, Denmark

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: complement, innate immunity and systemic lupus erythematosus (SLE)

Session Information

Date: Sunday, November 8, 2015

Title: Innate Immunity and Rheumatic Disease Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:
The complement system is one of the key players in the pathogenesis of
systemic lupus erythematosus (SLE). Collectin liver 1
(CL-L1) and collectin kidney 1 (CL-K1) are recently discovered complement pattern recognition
molecules. They form hetero-complexes termed
CL-LK that collaborate with associated serine proteases to activate the lectin
pathway of complement. The objective of this pilot study was to explore
the involvement of CL-LK in a cross-sectional cohort of SLE patients by
measuring plasma concentrations and analyze for
associations between the plasma concentrations and characteristic SLE
manifestations.

Methods: Prospectively, blood samples (citrated
plasma), ACR classification criteria and SLE disease activity index score
(SLEDAI) were collected from 58 SLE patients. Concentrations
in plasma of CL-L1 and CL-K1 were determined in the SLE patients and in age and
gender matched healthy controls using time resolved immuno-flourometric
assays developed in house.

Results:

RESULTS

SLE Patients (n=58)

Median plasma conc. ng/ml (range)

Healthy Controls (n=65)

Median plasma conc. ng/ml (range)

Mann-Whitney P value

CL-L1

252(159-365)

306(195-510)

< 0.001

CL-K1

326(221-447)

337(248-495)

0.033

Both the CL-L1 and CL-K1 concentrations were lower in SLE patients than
healthy controls (p <0.001 and 0.033).
Patients with low complement component 3 (C3)
demonstrated a negative correlation between C3 and CL-L1 and CL-K1 (p=0.022 and
0.031). The concentrations of CL-L1 and CL-K1 were highly correlated in both SLE patients and in healthy controls (r=0.576 and
r=0.592). We found no significant correlation between disease activity score or
organ damage score and plasma concentrations of CL-L1 or CL-K1.

Conclusion : In a cross-sectional
cohort of SLE patients, we found
differences in the plasma concentrations of CL-L1 and CL-K1 compared
to a group of healthy controls. We
observed a strong correlation between concentrations
of CL-L1 and CL-K1 in both SLE patients and healthy
controls substantiating the idea
of CL-L1 and CL-K1 being present as heterocomplexes in plasma.

The altered
concentrations found in SLE patients and associations
to elements of the disease, like hypocomplementemia, support
the hypothesis that the lectin pathway plays a role in the pathogenesis of SLE.

Disclosure: A. Troldborg, None; S. Thiel, None; L. Jensen, None; M. J. Laska, None; S. Hansen, None; B. Deleuran, None; J. C. Jensenius, None; K. Stengaard-Pedersen, None.

To cite this abstract in AMA style:

Troldborg A, Thiel S, Jensen L, Laska MJ, Hansen S, Deleuran B, Jensenius JC, Stengaard-Pedersen K. CL-L1 and CL-K1 Complement Associated Pattern Recognition Molecules in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/cl-l1-and-cl-k1-complement-associated-pattern-recognition-molecules-in-systemic-lupus-erythematosus/. Accessed .

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cl-l1-and-cl-k1-complement-associated-pattern-recognition-molecules-in-systemic-lupus-erythematosus/